

Product Name: Masitinib (AB1010) Revision Date: 01/10/2021

Product Data Sheet

Masitinib (AB101

Cat. No.:	A2942
CAS No.:	790299-79-5
Formula:	C28H30N6OS
M.Wt:	498.64
Synonyms:	
Target:	Tyrosine Kinase
Pathway:	c-Kit
Storage:	Store at -20°C
	a10

Solvent & Solubility

	\geq 24.95 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH				
In Vitro	Preparing Stock Solutions	Mass Solvent Concentration	1mg	5mg	10mg
	Slock Solutions	1 mM	2.0055 mL	10.0273 mL	20.0545 mL
	el0	5 mM	0.4011 mL	2.0055 mL	4.0109 mL
	PELE	10 mM	0.2005 mL	1.0027 mL	2.0055 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	Tyrosine kinase inhibitor,	Tyrosine kinase inhibitor, potent and selective		
IC ₅₀ & Target	200 nM (KIT), 540 nM (PE	200 nM (KIT), 540 nM (PDGFRα), 800 nM (PDGFRβ)		
	Cell Viability Assay			
	Cell Line:	Ba/F3 cells, HMC-1 α 155 and FMA3 cells, bone marrow cells		
	Preparation method:	The solubility of this compound in DMSO is > 25 mg/mL. General tips for		
In Vitro		obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes		
		and/or shake it in the ultrasonic bath for a while. Stock solution can be stored		
		below -20°C for several months.		
	Reacting conditions:	37°C		
		1 www.apexbt.com		

1 | www.apexbt.com

	Applications:	Masitinib inhibited human mast cell degranulation, cytokine production and
		migration of bone marrow cells. In Ba/F3 cells, masitinib dose-dependently
		inhibited cell proliferation induced by the V559D mutant, commonly associated
		with GIST (exon 11), with an IC50 of 3.0 \pm 0.1 nM. Masitinib dose-dependently
		inhibited $\Delta 27$ KIT-dependent proliferation of Ba/F3 cells with an IC50 of 5.0 =
	al0	0.3 nM. In HMC-1 α 155 and FMA3 cells, which carry KIT with mutations in the
	OE	juxtamembrane domain, the IC50 values were approximately 10 \pm 1 nM and 30
	ales Provent	\pm 1.5 nM, respectively. Masitinib inhibited SCF-stimulated cell proliferation and
		tyrosine phosphorylation of KIT with an IC50 of 200 \pm 50 nM. Masitinib inhibited
		cell growth and PDGFR phosphorylation in primary and metastatic ISS cell line
	Animal experiment	
	Animal models:	Ba/F3 Δ27 tumour model
	Dosage form:	Oral administration, 30, or 45 mg/kg, twice daily for 10 days
	Applications:	Mice treated with masitinib showed a dose-dependent inhibition of tumou
	610	growth. Masitinib at 30 or 45 mg/kg significantly reduced tumour growt
	OE CONTRACT	following 11 days of treatment compared to placebo, with average tumou
In Vivo	Provide Contraction	volume increases of 355% and 154%, respectively in the masitinib-treated
		mice. Orally administered masitinib at 100 mg/kg on mice having large $\Delta 2^{\circ}$
		KIT-expressing tumours. Masitinib (12.5 mg/kg/d, p.o.) increased overall TT
		(time-to-tumor progression) compared with placebo in dogs.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility ma
		slightly differ with the theoretical value. This is caused by an experimenta
		system error and it is normal.
	0	Blow
	C Var	PErson
Produc	t Citations	Particular
	Table 1	

See more customer validations on www.apexbt.com.

References



[1]. Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT[J]. PloS one, 2009, 4(9): e7258.

[2]. Lawrence J, Saba C, Gogal R, et al. Masitinib demonstrates anti - proliferative and pro - apoptotic activity in primary and metastatic feline injection - site sarcoma cells[J]. Veterinary and comparative oncology, 2012, 10(2): 143-154.

[3]. Hahn K A, Oglivie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors[J]. Journal of Veterinary Internal Medicine, 2008, 22(6): 1301-1309.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com







